Preclinical study reveals selective suppression of delayed type hypersensitivity by oral imidazo[2,1-b]benzothiazoles in mice, indicating potential as targeted immunosuppressive agents.
A series of 2-phenylimidazo[2,1-b]benzothiazole derivatives was prepared and tested for immunological activities. Some of the compounds showed significant suppressive activity of delayed type hypersensitivity (DTH) without inhibition of humoral immunity in mice by oral administration. The most active compound was 2-(m-hydroxyphenyl)imidazo[2,1-b]benzothiazole (20).
No takes yet. Share an insight, caveat, or question.
Mase et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: